Biotech Stock News: Amgen’s Blinatumomab Gets Priority Review
Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized. Late last week, Amgen (AMGN) provided an update on its cancer … Continue reading Biotech Stock News: Amgen’s Blinatumomab Gets Priority Review